• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Resideo Technologies Inc.

    11/14/24 2:12:23 PM ET
    $REZI
    Wholesale Distributors
    Industrials
    Get the next $REZI alert in real time by email
    SC 13G/A 1 rezia3_111424.htm BOSTON PARTNERS rezia3_111424.htm
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    SCHEDULE 13G
    Under the Securities Exchange Act of 1934
    (Amendment No. 3)*
    RESIDEO TECHNOLOGIES INC
    (Name of Issuer)
    Common Stock
    (Title of Class of Securities)
    76118Y104
    (CUSIP Number)
    September 30, 2024
    (Date of Event which Requires Filing of this Statement)
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    [X] Rule 13d-1(b)
    [   ] Rule 13d-1(c)
    [   ] Rule 13d-1(d)
    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see Instructions).
    CUSIP No.: 76118Y104
           
    1
    NAME OF REPORTING PERSON
    Boston Partners
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
    98-0202744
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) [   ]
    (b) [   ]
    3 SEC USE ONLY
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5
    SOLE VOTING POWER
    6,630,753
    6
    SHARED VOTING POWER
    0
    7
    SOLE DISPOSITIVE POWER
    7,592,402
    8
    SHARED DISPOSITIVE POWER
    0
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    7,592,402
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    [   ]
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    5.19%
    12
    TYPE OF REPORTING PERSON
    IA
    CUSIP No.: 76118Y104
    ITEM 1(a). NAME OF ISSUER:
    RESIDEO TECHNOLOGIES INC
    ITEM 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
    16100 N. 71st Street, Suite 550
    Scottsdale, Arizona 85254
    ITEM 2(a). NAME OF PERSON FILING:
    Boston Partners
    ITEM 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
    One Beacon Street 30th FL
    Boston, MA 02108
    ITEM 2(c). CITIZENSHIP:
    Delaware
    ITEM 2(d). TITLE OF CLASS OF SECURITIES:
    Common Stock
    ITEM 2(e). CUSIP NUMBER:
    76118Y104
    ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO SECTION 240.13d-1(b), or 13d-2(b) or (c) CHECK WHETHER THE PERSON FILING IS A:
    (a)
    [ ]
    Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78c);
    (b)
    [ ]
    Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)
    [ ]
    Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)
    [ ]
    Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);
    (e)
    [X]
    An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E);
    (f)
    [ ]
    An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F);
    (g)
    [ ]
    A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G);
    (h)
    [ ]
    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)
    [ ]
    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)
    [ ]
    A non-U.S. institution in accordance with 240.13d-1(b)(1)(ii)(J);
    (k)
    [ ]
    Group, in accordance with 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with 240.13d1(b)(1)(ii)(J), please specify the type of institution:
    ITEM 4. OWNERSHIP
    (a) Amount beneficially owned:
    7,592,402
    (b) Percent of class:
    5.19%
    (c) Number of shares as to which the person has:
    (i) sole power to vote or to direct the vote:
    Boston Partners : 6,630,753
    (ii) shared power to vote or to direct the vote:
    Boston Partners : 0
    (iii) sole power to dispose or direct the disposition of:
    Boston Partners : 7,592,402
    (iv) shared power to dispose or to direct the disposition of:
    Boston Partners : 0
    ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].
    ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:
    This Schedule is being filed with respect to 7,592,402 shares of RESIDEO TECHNOLOGIES INC
    (the Common Stock) held by Boston Partners on 09/30/2024 for the
    discretionary account of certain clients. By reason of rule 13d-3 under the act
    Boston Partners may be deemed to be a beneficial owner of such Common
    Stock. To the knowledge of Boston Partners no person has the right to receive
    or the power to direct the receipt of dividends from or the proceeds from the
    sale of such Common Stock which represents more than 5% of the
    outstanding shares of the Common Stock referred to in item 4(b) hereof.
    ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY:
    Not applicable
    ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP:
    Not applicable
    ITEM 9. NOTICE OF DISSOLUTION OF GROUP:
    Not applicable
    ITEM 10. CERTIFICATION:
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
    CUSIP No.: 76118Y104
    SIGNATURE
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
    November 14 2024
    Boston Partners
    By:
    /s/ Ali Farooqi
    Name:
    Ali Farooqi
    Title:
    Senior Compliance Analyst
    Attention — Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001).
    Get the next $REZI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $REZI

    DatePrice TargetRatingAnalyst
    4/22/2025$16.00Overweight → Neutral
    Analyst
    8/9/2024$25.00Outperform
    Evercore ISI
    7/5/2023$22.00Overweight
    JP Morgan
    11/2/2022$27.00Outperform → In-line
    Imperial Capital
    2/16/2022$31.00 → $30.00Equal-Weight
    Morgan Stanley
    10/6/2021$33.00 → $31.00Equal-Weight
    Morgan Stanley
    9/21/2021$36.00 → $33.00Equal-Weight
    Morgan Stanley
    More analyst ratings